Eli Lilly xStock
LLYX
Evaluation Score
Overall rating on a scale of 0-10
Dimension Breakdown
AI Analysis
Comprehensive evaluation of the token
LLYX (Eli Lilly xStock) is a real-world asset (RWA) token providing 1:1 backed economic exposure to Eli Lilly & Company equity, issued across multiple chains including Ethereum, Solana, and Arbitrum. From a development standpoint (Score: 7.0/10), the asset is actively maintained with multi-chain integrations and ongoing Proof-of-Reserve attestations. Team and Governance (Score: 6.0/10) benefits from the institutional strength and stability of Eli Lilly as the underlying corporate entity, though token holders possess no shareholder or onchain governance rights. Tokenomics (Score: 6.5/10) reflects standard 1:1 backing with an elastic supply, though centralization and counterparty risks remain inherent. Security and Audit History (Score: 5.5/10) reveals a clean operational record with zero reported hacks, depegs, or protocol exploits, balanced by an absence of published third-party smart contract audits. Major drawbacks are found in Community Support (Score: 1.5/10) and Market & Use Case (Score: 4.5/10), where adoption is minimal, holder distribution is extremely concentrated/thin, onchain trading liquidity is sparse, and ticker confusion exists with the unrelated Defiance 2X leveraged ETF. No qualifying red-flag events were identified.
Development Activity
Code updates and developer engagement
Community Support
Social media presence and community engagement
Tokenomics
Supply, distribution, and utility
Market & Use Case
Value proposition and competitive landscape
Team & Governance
Team background and project governance
Security & Audits
Security history and audit status
About Eli Lilly xStock (LLYX)
Eli Lilly xStock (LLYX) is a real-world asset (RWA) token designed to provide 1:1 backed economic exposure to the shares of pharmaceutical company Eli Lilly and Company. Issued as a tokenized equity product associated with Backed Assets and the xStocks platform, the token operates across multiple blockchain networks, including Ethereum, Solana, Arbitrum, BNB Smart Chain, Mantle, TON, and Optimism. Collateralization is maintained through underlying shares held in custody by regulated third-party institutions, complemented by automated continuous attestations such as Chainlink Proof of Reserve and The Network Firm. The token is distinct from the unrelated Defiance Daily Target 2X Long LLY ETF, which shares the LLYX ticker in traditional financial markets.
The token functions as a passive wrapper tracking the underlying equity's price rather than a traditional decentralized protocol. As such, it operates with an elastic supply model tied to minting and redemption demand, without native token inflation or on-chain governance mechanisms. Holding LLYX conveys economic exposure to Eli Lilly stock price movements but does not grant direct shareholder voting rights or participation in corporate governance.
From a security standpoint, the token has not experienced any smart contract exploits, protocol hacks, or depeg events. However, the token contracts lack published third-party smart contract audit reports. Market adoption remains limited, characterized by sparse daily trading volume, thin on-chain liquidity, conflicting supply reports across aggregators, and highly concentrated holder distribution. While the token itself has faced no direct regulatory actions, the underlying corporate entity, Eli Lilly and Company, historically settled FTC charges in 2002 regarding a 2001 inadvertent patient email disclosure breach.